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Edited by Gianni CesareniAbstract This study discovered that betulinic acid (BA) is a
potent proteasome activator that preferentially activates the
chymotrypsin-like activity of the proteasome. Chemical modiﬁ-
cations can transform BA into proteasome inhibitors. Chemical
modiﬁcations at the C-3 position of BA resulted in compounds,
such as dimethylsuccinyl BA (DSB), with various inhibitory
activities against the human 20S proteasome. Interestingly, the
proteasomal activation by BA and the inhibitory activity of
DSB could be abrogated by introducing a side chain at the C-
28 position. In summary, this study discovered a class of small
molecules that can either activate or inhibit human proteasome
activity depending on side chain modiﬁcations.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Betulinic acid; Proteasome inhibitor; Proteasome
activator1. Introduction
There are two major cellular proteolysis systems: lysosomes
and proteasomes. The proteasomes are responsible for the
majority of intracellular protein degradation. On the other
hand, lysosomes are critical for breaking down proteins taken
into cells through endocytosis [1,2]. The proteasome is in-
volved in many essential cellular functions, such as regulation
of cell cycle, cell diﬀerentiation, signal transduction pathways,
antigen processing for appropriate immune responses, stress
signaling, inﬂammatory responses, and apoptosis. Protea-
somes (20S) are cylindrical structures that contain four rings
stacked on top of each other. Each ring is composed of seven
subunits. The two outer rings contain a subunits and do not
have enzymatic activity. The two inner rings are comprised
of b subunits. These b subunits are where the proteolytic activ-
ities reside. There are three major proteolytic activities in the b
subunits: a chymotrypsin-like (b5), a trypsin-like (b2), and a
caspase-like (b1) activity. The 20S proteasome is normally
associated with 19S components to form the 26S proteasome.
The 19S components regulate the entry of proteins into the 20S
proteasome [3]. The 19S complex, also termed PA700, acti-
vates proteasome degradation of ubiquitin-conjugated pro-
teins. In addition to PA700, there are two other intracellularAbbreviations: BA, betulinic acid; DSB, dimethylsuccinyl betulinic acid
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doi:10.1016/j.febslet.2007.09.031protein complexes, PA28 and PA200, that can activate the
20S proteasome using peptide substrates as models [4–8].
Many proteasome inhibitors have been identiﬁed and can be
classiﬁed into two groups according to their source: chemically
synthesized small molecules and compounds derived from nat-
ural products [9]. The majority of chemically synthesized small
molecule proteasome inhibitors are peptide derivatives. The
peptide boronate PS341 (Bortezomib) was successfully devel-
oped into a useful anti-cancer drug for the treatment of multi-
ple myeloma [10]. In addition to the chemically synthesized
small molecules, natural products derived from plants, such
as the triterpene celastrol and withaferin A from traditional
herb medicine ‘‘Thunder-god vine’’ and Indian winter cherry,
respectively, were also shown to inhibit the proteasome at
low micromolar concentrations [11,12].
In contrast to the development of proteasome inhibitors,
drug-like small molecules that can activate or enhance protea-
some activity are rare. Several types of small molecules, includ-
ing denaturing reagents, lipids and peptide-based activators,
were shown to activate the 20S proteasome at relatively high
concentrations [13]. For example, SDS at 0.05%, polylysine
at 1mg/ml, and peptide-based activators at 100 lM were
shown to activate the 20S proteasome [14]. In this study, we
discovered that BA was a proteasome activator and modiﬁca-
tions at the C-3 position transformed BA into proteasome
inhibitors.2. Materials and methods
2.1. 20S proteasome assay
20S proteasome assay kits were purchased from Calbiochem, San
Diego, CA. The eﬀect of BA and its analogs on the 20S proteasome
activity was assayed following the protocol provided by the manufac-
turer. The major components of the assay mixture are human 20S pro-
teasomes, ﬂuorogenic peptide substrates and the proteasome activator
PA28. The assay was designed to measured hydrolysis of the ﬂuoro-
genic substrates Suc-Leu-Leu-Val-Tyr-AMC, (Z)-LLE-bNA, and
Bz-VGR-AMC in the presence of the proteasome activator, PA28.
Suc-Leu-Leu-Val-Tyr-AMC is frequently used to detect the chymo-
trypsin-like activity of the 20S proteasome. The trypsin-like and cas-
pase-like activities of the 20S proteasome were determined using the
ﬂuorogenic substrates Bz-VGR-AMC and (Z)-LLE-bNA, respectively.
Fluorescence generated from the proteolytic reaction in the presence of
various concentrations of BA or its analogs was measured using a Bio-
Tek ﬂuorometer (Winooski, Vermont).
To determine the proteasome activation activity of the compounds,
PA28 was omitted from the reaction mixtures. The rate of cleavage
reaction is expressed as the slope of each line (DRFU(360/460)/min)
in the plots. The 50% eﬀective concentration for activation (EC50) is
deﬁned as the activator concentration that reaches 50% of maximal
reaction rate. The rate of reaction was plotted against the log-concen-
tration of the activator to determine the EC50.blished by Elsevier B.V. All rights reserved.
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were tested in the presence of 16 lg/ml of PA28. The 50% inhibitory
concentration (IC50) is deﬁned as the inhibitor concentration that re-
duces the reaction rate by 50%. The velocity of reaction (DRFU(360/
460)/min) was plotted against the log-concentration of the inhibitor
to determine the IC50.
2.2. Cell-based proteasome assay
To determine the eﬀect of BA derivatives on the proteasome in cul-
ture cells, a Promega cell-based assay was used in this study. MT4 cells
(4000 cells) were treated with BA derivatives or the proteaome inhibi-
tor LLM-f (Boston Biochem, Cambridge, MA, USA) in serum free
medium at 37 C for 3 h. MT4 cells are human T cells isolated from
a patient with adult T-cell leukemia. MT4 cells were obtained from
the NIH AIDS Research and Reference Reagent Program. The
drug-treated MT4 cells were incubated with the Promega Protea-
some-Glo Cell-Based Assay Reagent (Promega Bioscience, Madison,
WI) for 10 min. The chymotrypsin-like proteasome activity was de-
tected as the relative light unit (RLU) generated from the cleaved sub-
strate in the reaction mixture. Luminescence generated from each
reaction condition was detected with a Perkin-Elmer Victor-3 lumino-
meter (Shelton, CT, USA).Fig. 2. BA preferentially activated chymotrypsin-like proteasome
activity. Eﬀects of BA on the chymotrypsin-like activity (A), trypsin-
like activity (B), and caspase-like activity (C) of the proteasome were
determined in the absence of PA28.3. Results
We and others have studied the anti-HIV-1 activity of BA
and its derivatives [15–22]. In an eﬀort to identify potential cel-
lular targets of these compounds, BA was tested against the
human 20S proteasome. The chemical structure of BA is
shown in Fig. S1 (supplemental data). BA did not inhibit the
chymotrypsin-like activity of the proteasome (Fig. 1). In fact,
the chymotrypsin-like activity was enhanced in the presence
of BA. This result raised the possibility that BA could act as
a proteasome activator. To test this possibility, the proteasome
activator, PA28, was left out of the reaction mixtures. In the
absence of PA28, the 20S proteasome is inactive. BA was able
to activate the chymotrypsin-like activity of 20S proteasome in
a dose dependent manner (Fig. 2A). The reaction rate reached
a plateau with BA at 10 lg/ml. The concentration of BA re-
quired to achieve 50% activation (EC50) is approximately
2.5 lg/ml.
Although BA can activate the proteasome activity, its mode
of action is clearly diﬀerent from that of PA28 or sodium dode-
cyl sulfate (SDS). PA28 and SDS are two proteasome activa-
tors that are commonly used in proteasome assays. Both
PA28 and SDS can activate the three main proteasome activ-
ities: chymotrypsin-like, trypsin-like, and caspase-like activi-
ties. In contrast, BA did not activate the trypsin-like activityFig. 1. BA enhanced the chymotrypsin-like activity of the 20S
proteasome. The cleavage of the proteasome substrate Suc-Leu-Leu-
Val-Tyr-AMC in the presence of PA28 was quantiﬁed with the relative
ﬂuorescence units (RFU) measured at 360/460 nm over a 20 min
reaction time.and exhibited minimal activation on the caspase-like activity
of the proteasome (Figs. 2B and C). PA28 activates protea-
some by inducing conformational changes in the proteasome,
which allows the proteasome substrates to access the proteo-
lytic sites inside the 20S proteasome cylinder. On the other
hand, SDS activates the proteasome presumably by partially
denaturing the 20S proteasome, and that allows substrates to
access the catalytic sites. Therefore, BA appears to activate
the chymotrypsin-like activity in a mode distinct from that
of PA28 or SDS.
Activation of the proteasome by BA raised the possibility
that BA derivatives might also activate the proteasome. There
are three sites on the BA structure that can be used for chem-
ical modiﬁcations: C-3, C-20, and C-28. We have previously
shown that the anti-HIV-1 activity of BA derivatives is highly
dependent on where their side chain modiﬁcation resides
[21,22]. A series of BA derivatives with modiﬁcation at C-3
and C-28 positions were tested for their eﬀect on 20S protea-
somes. Instead of activation of the proteasome, some of the
tested BA derivatives inhibited the chymotrypsin-like activity
at low lg/ml concentrations (Table 1).
A typical example of BA derivatives that inhibited 20S pro-
teasomes is shown in Fig. 3. The BA derivative 3 0,3 0-dimethyl-
succinyl BA (DSB, 2) inhibited the chymotrypsin-like activity
of the 20S proteasome by 50% at a concentration of approxi-
mately 4 lg/ml (Fig. 3A). However, DSB with an additional
side chain modiﬁcation at position C-28 (compound LH141,
7) was inactive against the proteasome (Table 1). The BA
derivative IC9564 (8) with the same C-28 side chain as
LH141 was also inactive (Table 1). This C-28 side chain also
Table 1
Eﬀect of BA derivatives on the chymotrypsin-like activity of the 20S proteasome
R1O
O
R2
H
H
H
H3
28
Betulinic acid: R1 = R2 = H
Compounds Structures IC50# (lg/ml)
R1 R2
DSB*1 (2)
O
HOOC OH 4.0
A15*1 (3)
O
HOOC OH 8.2
A16*1 (4) O
O
HOOC OH >20
A18*1 (5)
OHOOC OH >20
LH68*1 (6) HOOC
O
OH 6.5
LH141*2 (7) O
HOOC NH(CH2)7-C-NH
O
OH
COOH >20
IC9564*2 (8) H NH(CH2)7-C-NH
O
OH
COOH >20
The chemical structures and characteristics of these compounds are described in Refs. [16] (*1) and [22] (*2).
#: The IC50 values in the table are the average of three experiments.
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did not activate the 20S proteasome in the absence of PA28
(data not shown). These results suggested that the C-3 modiﬁ-
cations could transform BA from a proteasome activator into
an inhibitor and addition of a side chain at C-28 could nullify
the activation activity of BA and inhibitory activity of DSB.
The trypsin-like activity of the proteasome was less sensitive
to DSB. It took approximately 12 lg/ml of DSB to inhibit the
trypsin-like activity by 50% (Fig. 3B). On the other hand, DSB
did not inhibit the caspase-like activity of the proteasome
(Fig. 3C). These results suggested that BA derivatives can be-
come a new class of proteasome inhibitors that preferentially
inhibit chymotrypsin-like activity of the proteasome.
Inhibition of the proteasome by DSB could be a result of
competition with the cellular proteasome activator, PA28, in
the reaction mixture. To test this possibility, PA28 was re-
placed with 0.03% SDS as proteasome activator in the assay
mixture. Under this assay condition, DSB inhibited the protea-
some activity by 50% at approximately 3 lg/ml (Fig. 4). This
inhibitory activity is comparable to that when PA28 was used
as the proteasome activator (Fig. 3A). Therefore, the data sug-
gest that the inhibitory activity of DSB is not due to the inhi-
bition of PA28 binding to the proteasome.
Although DSB could inhibit the puriﬁed proteasome, it is
not clear whether the compound can eﬀectively inhibit protea-
somes in the cells. To determine the eﬀect of DSB on the pro-teasome in living cells, MT4 cells were treated with DSB or a
known proteasome inhibitor Ac-Leu-Leu-Met-CHO (LLM-
f). The chymotrypsin-like activity of the proteasome in the cells
was analyzed using a Promega cell-based proteasome assay.
DSB eﬀectively inhibited the proteasome activity with an
IC50 approximately 2 lg/ml (Fig. 5). Thus, DSB is approxi-
mately 2-fold more potent in the cell-based assay than in the
assays using the puriﬁed proteasome. It is not clear why
DSB is slightly more potent in the cell-based assay than in
the puriﬁed proteasome assay. One possible explanation is that
DSB might have accumulated to a higher concentration in the
cells.4. Discussion
The results of this study demonstrated that BA could di-
rectly interact with the puriﬁed proteasome and preferentially
activate the chymotrypsin-like activity of the proteasome with
minimal eﬀect on the trypsin-like and caspase-like activities of
the proteasome. This is consistent with the ﬁnding that BA-in-
duced degradation of transcription factors in LNCaP cells
could be abrogated by proteasome inhibitors, such as
MG132 [23]. Other than proteasome activation, BA was
shown to induce apoptosis by direct eﬀects on mitochondria
leading to cytochrome-c release [24–27]. Cytochrome-c release
Fig. 3. The BA derivative, DSB, preferentially inhibited chymotryp-
sin-like proteasome activity. The chymotrypsin-like activity (A),
trypsin-like activity (B), and caspase-like activity (C) of the proteasome
were determined in the presence of various concentrations of DSB as
indicated.
Fig. 4. DSB inhibited SDS-activated chymotrypsin-like proteasome
activity. The SDS-activated chymotrypsin-like activity of the protea-
some was determined in the presence of various concentrations of DSB
as indicated.
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Fig. 5. DSB inhibited the chymotrypsin-like proteasome activity in
MT4 cells. MT4 cells were treated with various concentrations of DSB
or LLM-F as indicated. Each data point represents the means ± S.D.
of three duplicated experiments.
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tion and ultimately leads to cell death. BA was shown to inhi-
bit the growth of melanoma cell lines at low micromolar
concentrations. Due to its potential anti-cancer activity, BA
is currently undergoing phase II clinical trials for dysplastic
melanocytic nevus (web site: ClinicalTrials.gov).
While BA is promising for its anti-cancer activity, BA deriv-
atives have been extensively studied for their potential as anti-HIV agents. The mechanism of anti-HIV action is dependent
on side chain locations. BA derivatives with C-3-hydroxyl
esteriﬁed compounds inhibited HIV-1 replication by interfer-
ing with HIV-1 maturation [28,29]. DSB (also designated as
Bevirimat) is a typical C-3 substituted BA derivative exhibiting
potent anti-HIV-1 activity [15,16]. DSB is currently under
phase II clinical trial as an orally active anti-HIV-1 drug.
DSB at a daily dose of 100mg resulted in a peak plasma con-
centration over 30 lg/ml (Martin, D. et al. Abstract 551, 12th
Conference on Retroviruses and Opportunistic Infection,
2005). The inhibitory activity of DSB on the proteasome might
have the potential to cause side eﬀects if the compound is used
for AIDS therapy, especially if the plasma concentration of
DSB is higher than the concentration that inhibits protea-
somes.
In contrast to the anti-HIV-1 maturation activity of the C-3
derivatives, BA derivatives with a side chain modiﬁcation at C-
28 inhibited HIV-1 entry. For example, IC9564 is a C-28
substituted BA derivative that blocks HIV-1 entry [17]. Unlike
DSB, IC9564 did not aﬀect the 20S proteasome.
Although targeting the proteasome might be a concern if the
C-3 substituted BA derivatives are used as anti-viral agents,
the most important attribute of this study is the potential clin-
ical and biomedical applications of the proteasome activators
and inhibitors due to the importance of the proteasome in mul-
tiple cellular processes. For example, the proteasome inhibitor
Bortezomib was successfully developed into a useful anti-can-
cer drug for the treatment of multiple myeloma [10]. In addi-
tion, over-expression of the proteasome activator PA28 was
shown to enhance survival of Huntington’s disease (HD) neu-
ronal model cells [30].
In summary, the results of this study indicate that BA pref-
erentially activates the chymotrypsin-like activity of protea-
somes. BA can be transformed into proteasome inhibitors by
simple chemical modiﬁcations at the C-3 position of the mole-
cules. It would be interesting to study whether BA could have
beneﬁcial eﬀects on neurodegenerative diseases, such as Hun-
tington’s disease. In addition, BA derivatives that inhibit the
proteasome might have the potential to be developed into ther-
apeutics for cancers or inﬂammatory diseases.
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